|Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma|
M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ...
New England Journal of Medicine 357 (21), 2123-2132, 2007
|Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma|
RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ...
Journal of clinical oncology 27 (32), 5410, 2009
|Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy|
B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, ...
Journal of Clinical Oncology 30 (6), 631-636, 2012
|Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma|
H Quach, D Ritchie, AK Stewart, P Neeson, S Harrison, MJ Smyth, ...
Leukemia 24 (1), 22, 2010
|Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation …|
A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, ...
J Clin Oncol 27 (11), 1788-1793, 2009
|Clinical studies of histone deacetylase inhibitors|
HM Prince, MJ Bishton, SJ Harrison
Clinical Cancer Research 15 (12), 3958-3969, 2009
|Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma|
RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, ES Jaffe, ...
Blood 117 (22), 5827-5834, 2011
|Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United …|
EA Olsen, S Whittaker, YH Kim, M Duvic, HM Prince, SR Lessin, GS Wood, ...
Journal of Clinical Oncology 29 (18), 2598, 2011
|EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary …|
W Kempf, K Pfaltz, MH Vermeer, A Cozzio, PL Ortiz-Romero, M Bagot, ...
Blood 118 (15), 4024-4035, 2011
|Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma|
L Ellis, Y Pan, GK Smyth, DJ George, C McCormack, R Williams-Truax, ...
Clinical Cancer Research 14 (14), 4500-4510, 2008
|Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia|
BJP Huntly, AG Reid, AJ Bench, LJ Campbell, N Telford, P Shepherd, ...
Blood 98 (6), 1732-1738, 2001
|A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease|
MED Flowers, JF Apperley, K van Besien, A Elmaagacli, A Grigg, V Reddy, ...
Blood 112 (7), 2667-2674, 2008
|Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia|
DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, ...
Molecular Therapy 21 (11), 2122-2129, 2013
|Histone deacetylase inhibitors in cancer therapy|
WK Rasheed, RW Johnstone, HM Prince
Expert opinion on investigational drugs 16 (5), 659-678, 2007
|Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study|
A Younes, A Sureda, D Ben-Yehuda, PL Zinzani, TC Ong, HM Prince, ...
Journal of Clinical Oncology 30 (18), 2197-2203, 2012
|Breast implant–associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients|
RN Miranda, TN Aladily, HM Prince, R Kanagal-Shamanna, D De Jong, ...
Journal of Clinical Oncology 32 (2), 114, 2014
|Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring|
L Mileshkin, R Stark, B Day, JF Seymour, JB Zeldis, HM Prince
Journal of Clinical Oncology 24 (27), 4507-4514, 2006
|How I treat mycosis fungoides and Sézary syndrome|
HM Prince, S Whittaker, RT Hoppe
Blood 114 (20), 4337-4353, 2009
|Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma|
HM Prince, M Duvic, A Martin, W Sterry, C Assaf, Y Sun, D Straus, ...
Clinical Oncology, 2007
|Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab|
KA Thursky, LJ Worth, JF Seymour, H Miles Prince, MA Slavin
British journal of haematology 132 (1), 3-12, 2006